Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/ijms23084305
Keywords
non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); type 2 diabetes mellitus; peroxisome proliferator-activated receptors (PPAR)
Funding
- Swiss Liver Foundation
- Gottfried and Julia Bangerter-Rhyner Foundation
- Swiss Academy of Medical Sciences (SAMS)
Ask authors/readers for more resources
This review discusses the evidence of PPAR-targeted treatment for NAFLD and NASH in individuals with type 2 diabetes mellitus, as well as the impact on comorbid metabolic conditions. Future research may focus on the sexually dimorphic effects of PPAR-targeted therapies.
Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of the nuclear hormone receptor superfamily, have been identified as key metabolic regulators in the liver, skeletal muscle, and adipose tissue, among others. As a leading cause of liver disease worldwide, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) cause a significant burden worldwide and therapeutic strategies are needed. This review provides an overview of the evidence on PPAR-targeted treatment of NAFLD and NASH in individuals with type 2 diabetes mellitus. We considered current evidence from clinical trials and observational studies as well as the impact of treatment on comorbid metabolic conditions such as obesity, dyslipidemia, and cardiovascular disease. Future areas of research, such as possible sexually dimorphic effects of PPAR-targeted therapies, are briefly reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available